Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

JAK1 inhibitor

- PMLiVE

New EU and US approvals for Humira biosimilars

Samsung’s Imraldi and Boehringer Ingelheim’s Cyltezo receives nod from EMA and FDA, respectively

- PMLiVE

SMC gives green light for Amgen’s Kyprolis

The committee also gives verdict on three other products

- PMLiVE

SMC gives green light for Amgen’s Kyprolis

The committee also gives verdict on three other products

Sanofi reception

Sanofi and Regeneron bag EU approval for arthritis drug Kevzara

The IL-6 inhibitor will be used in combination with methotrexate for adults with RA

- PMLiVE

Samsung Bioepis wins CHMP nod for second Humira biosimilar

In addition to Imraldi the regulatory advisors also backed new medicines from AbbVie and Gilead

- PMLiVE

Lilly and NRAS launch arthritis awareness film campaign

Pharma firm's ‘Behind The Smile’ initiative coincides with RA awareness week

- PMLiVE

AbbVie appoints new GMs for France and the UK

Jérôme Bouyer and Pierre-Claude Fumoleau take up new roles at the pharma firm

EU flag

CHMP backs two rare disease therapies at April meeting

Biogen's Spinraza and BioMarin's Brineura near EU approval

- PMLiVE

AbbVie’s PARP inhibitor veliparib fails to deliver

Phase III trials show no increase in clinical benefit

Eli Lilly HQ

FDA turns down Lilly and Incyte JAK inhibitor after delay

Analysts suggest safety issues in high doses

- PMLiVE

AbbVie and J&J file first non-cancer use for Imbruvica with FDA

Seeks FDA approval to treat GVHD patients

- PMLiVE

Mundipharma to launch first MabThera biosimilar in EU

EMA approves Truxima in all indications licensed to Roche’s cancer drug

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links